Literature DB >> 21737801

Programmed death-1 pathway limits central nervous system inflammation and neurologic deficits in murine experimental stroke.

Xuefang Ren1, Kozaburo Akiyoshi, Arthur A Vandenbark, Patricia D Hurn, Halina Offner.   

Abstract

BACKGROUND AND
PURPOSE: Evaluation of infarct volumes and infiltrating immune cell populations in mice after middle cerebral artery occlusion strongly implicates a mixture of both pathogenic and regulatory immune cell subsets that affect stroke outcome. Our goal was to evaluate the contribution of the well-described coinhibitory pathway, programmed death (PD)-1, to the development of middle cerebral artery occlusion.
METHODS: Infarct volumes, functional outcomes, and effects on infiltrating immune cell populations were compared in wild-type C57BL/6 versus PD-1-deficient mice after 60 minutes middle cerebral artery occlusion and 96 hours reperfusion.
RESULTS: The results clearly demonstrate a previously unrecognized activity of the PD-1 pathway to limit infarct volume, recruitment of inflammatory cells from the periphery, activation of macrophages and central nervous system microglia, and functional neurological deficits. These regulatory functions were associated with increased percentages of circulating PD-ligand-1 and PD-ligand-2 expressing CD19(+) B-cells in blood, the spleen, and central nervous system with the capacity to inhibit activation of inflammatory T-cells and central nervous system macrophages and microglial cells through upregulated PD-1.
CONCLUSIONS: Our novel observations are the first to implicate PD-1 signaling as a major protective pathway for limiting central nervous system inflammation in middle cerebral artery occlusion. This inhibitory circuit would likely be pivotal in reducing stroke-associated Toll-like receptor-2- and Toll like receptor-4-mediated release of neurotoxic factors by activated central nervous system microglia.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21737801      PMCID: PMC3164218          DOI: 10.1161/STROKEAHA.111.613182

Source DB:  PubMed          Journal:  Stroke        ISSN: 0039-2499            Impact factor:   7.914


  29 in total

1.  PD-1 immunoreceptor inhibits B cell receptor-mediated signaling by recruiting src homology 2-domain-containing tyrosine phosphatase 2 to phosphotyrosine.

Authors:  T Okazaki; A Maeda; H Nishimura; T Kurosaki; T Honjo
Journal:  Proc Natl Acad Sci U S A       Date:  2001-11-06       Impact factor: 11.205

Review 2.  The PD-1-PD-L pathway in immunological tolerance.

Authors:  Taku Okazaki; Tasuku Honjo
Journal:  Trends Immunol       Date:  2006-02-24       Impact factor: 16.687

3.  Contribution of the PD-1 ligands/PD-1 signaling pathway to dendritic cell-mediated CD4+ T cell activation.

Authors:  Harmjan Kuipers; Femke Muskens; Monique Willart; Daniëlle Hijdra; Friso B J van Assema; Anthony J Coyle; Henk C Hoogsteden; Bart N Lambrecht
Journal:  Eur J Immunol       Date:  2006-09       Impact factor: 5.532

Review 4.  The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection.

Authors:  Arlene H Sharpe; E John Wherry; Rafi Ahmed; Gordon J Freeman
Journal:  Nat Immunol       Date:  2007-03       Impact factor: 25.606

5.  Splenic atrophy in experimental stroke is accompanied by increased regulatory T cells and circulating macrophages.

Authors:  Halina Offner; Sandhya Subramanian; Susan M Parker; Chunhe Wang; Michael E Afentoulis; Anne Lewis; Arthur A Vandenbark; Patricia D Hurn
Journal:  J Immunol       Date:  2006-06-01       Impact factor: 5.422

Review 6.  The PD-1 pathway in tolerance and autoimmunity.

Authors:  Loise M Francisco; Peter T Sage; Arlene H Sharpe
Journal:  Immunol Rev       Date:  2010-07       Impact factor: 12.988

7.  Microglial expression of the B7 family member B7 homolog 1 confers strong immune inhibition: implications for immune responses and autoimmunity in the CNS.

Authors:  Tim Magnus; Bettina Schreiner; Thomas Korn; Carolyn Jack; Hong Guo; Jack Antel; Igal Ifergan; Lieping Chen; Felix Bischof; Amit Bar-Or; Heinz Wiendl
Journal:  J Neurosci       Date:  2005-03-09       Impact factor: 6.167

8.  Immunological studies on PD-1 deficient mice: implication of PD-1 as a negative regulator for B cell responses.

Authors:  H Nishimura; N Minato; T Nakano; T Honjo
Journal:  Int Immunol       Date:  1998-10       Impact factor: 4.823

9.  SHP-1 and SHP-2 associate with immunoreceptor tyrosine-based switch motif of programmed death 1 upon primary human T cell stimulation, but only receptor ligation prevents T cell activation.

Authors:  Jens M Chemnitz; Richard V Parry; Kim E Nichols; Carl H June; James L Riley
Journal:  J Immunol       Date:  2004-07-15       Impact factor: 5.422

10.  Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death.

Authors:  Y Ishida; Y Agata; K Shibahara; T Honjo
Journal:  EMBO J       Date:  1992-11       Impact factor: 11.598

View more
  37 in total

1.  Varicella-Zoster Virus Downregulates Programmed Death Ligand 1 and Major Histocompatibility Complex Class I in Human Brain Vascular Adventitial Fibroblasts, Perineurial Cells, and Lung Fibroblasts.

Authors:  Dallas Jones; Anna Blackmon; C Preston Neff; Brent E Palmer; Don Gilden; Hussain Badani; Maria A Nagel
Journal:  J Virol       Date:  2016-11-14       Impact factor: 5.103

2.  PD-L1 mediated the differentiation of tumor-infiltrating CD19+ B lymphocytes and T cells in Invasive breast cancer.

Authors:  Honggeng Guan; Yang Lan; Yuqiu Wan; Qin Wang; Cheng Wang; Longjiang Xu; Yongjing Chen; Wenting Liu; Xueguang Zhang; Yecheng Li; Yongping Gu; Zemin Wang; Fang Xie
Journal:  Oncoimmunology       Date:  2015-08-12       Impact factor: 8.110

3.  Myelin specific cells infiltrate MCAO lesions and exacerbate stroke severity.

Authors:  Xuefang Ren; Kozaburo Akiyoshi; Marjorie R Grafe; Arthur A Vandenbark; Patricia D Hurn; Paco S Herson; Halina Offner
Journal:  Metab Brain Dis       Date:  2011-10-12       Impact factor: 3.584

Review 4.  Long-term T cell responses in the brain after an ischemic stroke.

Authors:  Uma Maheswari Selvaraj; Ann M Stowe
Journal:  Discov Med       Date:  2017-12       Impact factor: 2.970

5.  PD-L1 Monoclonal Antibody Treats Ischemic Stroke by Controlling Central Nervous System Inflammation.

Authors:  Sheetal Bodhankar; Yingxin Chen; Andrew Lapato; Abby L Dotson; Jianming Wang; Arthur A Vandenbark; Julie A Saugstad; Halina Offner
Journal:  Stroke       Date:  2015-08-25       Impact factor: 7.914

6.  Essential role of program death 1-ligand 1 in regulatory T-cell-afforded protection against blood-brain barrier damage after stroke.

Authors:  Peiying Li; Leilei Mao; Xiangrong Liu; Yu Gan; Jing Zheng; Angus W Thomson; Yanqin Gao; Jun Chen; Xiaoming Hu
Journal:  Stroke       Date:  2014-02-04       Impact factor: 7.914

7.  A novel hypothesis: regulatory B lymphocytes shape outcome from experimental stroke.

Authors:  Halina Offner; Patricia D Hurn
Journal:  Transl Stroke Res       Date:  2012-05-09       Impact factor: 6.829

Review 8.  Inflammatory CNS disease caused by immune checkpoint inhibitors: status and perspectives.

Authors:  Lidia M Yshii; Reinhard Hohlfeld; Roland S Liblau
Journal:  Nat Rev Neurol       Date:  2017-11-06       Impact factor: 42.937

9.  Programmed Death Ligand-1 on Microglia Regulates Th1 Differentiation via Nitric Oxide in Experimental Autoimmune Encephalomyelitis.

Authors:  Jingxia Hu; Hao He; Zhengang Yang; Guangming Zhu; Li Kang; Xiuli Jing; Hai Lu; Wengang Song; Bo Bai; Hua Tang
Journal:  Neurosci Bull       Date:  2016-01-14       Impact factor: 5.203

10.  IL-10-producing B-cells limit CNS inflammation and infarct volume in experimental stroke.

Authors:  Sheetal Bodhankar; Yingxin Chen; Arthur A Vandenbark; Stephanie J Murphy; Halina Offner
Journal:  Metab Brain Dis       Date:  2013-05-03       Impact factor: 3.584

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.